Researchers Halt Trial of Promising Sickle Cell Treatment


Two patients in a gene therapy study developed cancer years after treatment. It is not clear whether the therapy was responsible. (Ny Times Science) More More

Similar stories

CRISPR Clinical Trials: A 2021 Update - Newswise

CRISPR Clinical Trials: A 2021 Update  Newswise

Posted on 3 March 2021 | 1:25 pm | Google News

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 - BioSpace

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1  BioSpace

Posted on 3 March 2021 | 5:32 am | Google News

US halts trial of Covid-19 convalescent plasma - ETHealthworld.com

US halts trial of Covid-19 convalescent plasma  ETHealthworld.com

Posted on 3 March 2021 | 4:10 am | Google News

Mesoblast gets a $110M lifeline from SurgCenter Development; uniQure still unsure if gene therapy spurred cancer event - Endpoints News

Mesoblast gets a $110M lifeline from SurgCenter Development; uniQure still unsure if gene therapy spurred cancer event  Endpoints News

Posted on 28 February 2021 | 3:00 am | Google News

EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients - PRNewswire

EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients  PRNewswire

Posted on 26 February 2021 | 6:46 am | Google News

Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript - Motley Fool

Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript  Motley Fool

Posted on 25 February 2021 | 9:30 pm | Google News

Copyright © 2021 LastMinuteStuff.com | Contact info